Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Abatacept Placebo Clear all
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

NCT05822583
View directory record Official record
Conditions
COVID-19
Interventions
abatacept infusion, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
82
States / cities
Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

NCT00784459
View directory record Official record
Conditions
Atopic Asthma
Interventions
abatacept, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

NCT03215927
View directory record Official record
Conditions
Myositis, Interstitial Lung Disease
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 4, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

NCT02161406
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 4, 2026, 2:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 4, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

NCT04925375
View directory record Official record
Conditions
Interstitial Lung Disease, Common Variable Immunodeficiency
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Recruiting Phase 3 Interventional

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928
View directory record Official record
Conditions
Myocarditis Acute, Cancer
Interventions
Abatacept plus, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
29
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Abatacept as GVHD Prophylaxis Phase 2

NCT01743131
View directory record Official record
Conditions
Graft vs Host Disease, Malignancy
Interventions
Abatacept, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Oakland, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 4, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
10
States / cities
Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Subcutaneous Pharmacokinetics of Belatacept

NCT00569803
View directory record Official record
Conditions
Transplantation
Interventions
belatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

NCT00048581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

The Study of Abatacept in Combination With Etanercept

NCT00162279
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
35
States / cities
Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

NCT01142726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 4, 2026, 2:37 PM EDT
Withdrawn Phase 2 Interventional

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

NCT01917058
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept, placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 4, 2026, 2:37 PM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 4, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

NCT00277225
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 4, 2026, 2:37 PM EDT